Clinical results of EGFR-targeted therapies in advanced colorectal cancer

Evaristo Maiello, Vittorio Gebbia, Luigi Manzione, Francesco Giuliani, Franco Morelli, Carlo Arcara, Antonio Grimaldi, Giuseppe Colucci

Research output: Contribution to journalArticlepeer-review


This paper is an updated review of the pre-clinical rationale and clinical results of new EGFR-targeted agents - cetuximab and panitumumab - employed in the management of advanced/ metastatic colorectal cancer. The addition of either biologic agent or last generation standard chemotherapy regimens - FOLFIRI and FOLFOX - has yielded better results as compared to those reported for chemotherapy alone. These results have been obtained without a significant increase in severe toxicity with the exception of skin side-effects.

Original languageEnglish
Pages (from-to)64-69
Number of pages6
JournalEuropean Journal of Cancer, Supplement
Issue number14
Publication statusPublished - Oct 2008


  • Cetuximab
  • Colorectal cancer
  • Panitumumab

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Clinical results of EGFR-targeted therapies in advanced colorectal cancer'. Together they form a unique fingerprint.

Cite this